Savient's Gout Therapy Krystexxa Delayed At FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The biggest delay in Savient's resubmission of its gout therapy Krystexxa (pegloticase) could come from FDA's request that the sponsor include detailed materials for its Risk Evaluation and Mitigation Strategy as part of the resubmission